ChiCTR1900025089: Phase I study for CTA101 UCART cells injection in the treatment of relapsed or refractory CD19+ acute B-lymphocytic leukemia and diffuse large B-cell lymphoma |
|
|
| Recruiting | N/A | 18 | | infusion of 0.1×10^6 CAR+ T Cells/kg ;infusion of 1×10^6 CAR+ T Cells/kg ;infusion of 3×10^6 CAR+ T Cells/kg ;Infusion of 0.2×10^6 CAR+ T Cells/kg ;Infusion of 2×10^6 CAR+ T Cells/kg ;Infusion of 3×10^6 CAR+ T Cells/kg | The First Affiliated Hospital of Xiamen University; Level of the institution：, Nanjing Bioheng Biotech Co., Ltd. | CD19+ acute B-lymphocytic leukemia and diffuse large B-cell lymphoma | | | | |
ChiCTR1900027390: Study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia |
|
|
| Not yet recruiting | N/A | 18 | | infuse 0.3×10^6 CAR+ T Cells/kg ;infuse 0.6×10^6 CAR+ T Cells/kg ;infuse 1.0×10^6 CAR+ T Cells/kg | Hebei Yanda Lu Daopei Hospital; Hebei Yanda Lu Daopei Hospital, Nanjing Bioheng Biotech Co.， LTD | relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia | | | | |
